The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...

This interim data analysis from the phase 3 DESTINY-Breast03 trial evaluated progression-free survival, overall survival, objective response, and safety between patients with metastatic breast cancer ...

SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO – Safety outcomes with first-line ado-trastuzumab emtansine in the final descriptive analysis of the ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Adjuvant ado-trastuzumab emtansine reduced risk for invasive recurrence by 50% compared with ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Genentech announced topline results of EMILIA, a randomized Phase 3 study of trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. The study showed people who received ...

Patients received ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression. The primary end point was overall response rate using Response Evaluation Criteria in Solid ...

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

GenentechMedia Contact:Susan Willson, 650-467-6800Advocacy Contact:Sonali Padhi, 650-467-0842Investor Contacts:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 Genentech, a member of ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), the technical report, and responses from stakeholders. See the committee ...

GenentechMedia Contact:Susan Willson, 650-467-6800Advocacy Contact:Sonali Padhi, 650-467-0842Investor Contacts:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 Genentech, a member of ...